amatuximab

Home
Ligands
amatuximab

GtoPdb Ligand ID: 7750

Synonyms: MORAb-009

Comment: Amatuximab is a chimeric monoclonal antibody to mesothelin (MSLN; Q13421), a cell surface glycoprotein highly expressed in malignant pleural mesothelioma, all pancreatic adenocarcinoma, the majority of ovarian adenocarcinoma, as well as in non-small cell lung and colorectal cancers[5].
The crystal structure of the Fab fragment of amatuximab in complex with a mesothelin fragment (amino acids 7-64) has been deposited in Protein Data Bank with accession 4F33 [4].

References
1. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D. (2010) Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res, 16 (24): 6132-8. [PMID:21037025]
2. Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L et al.. (2007) Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun, 7: 20. [PMID:18088084]
3. Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P et al.. (2014) Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res, 20 (23): 5927-36. [PMID:25231400]
4. Ma J, Tang WK, Esser L, Pastan I, Xia D. (2012) Characterization of crystals of an antibody-recognition fragment of the cancer differentiation antigen mesothelin in complex with the therapeutic antibody MORAb-009. Acta Crystallogr Sect F Struct Biol Cryst Commun, 68 (Pt 8): 950-3. [PMID:22869130]
5. Tang Z, Qian M, Ho M. (2013) The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med Chem, 13 (2): 276-80. [PMID:22721387]

References

1. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D. (2010)
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.
Clin Cancer Res, 16 (24): 6132-8. [PMID:21037025]

2. Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L et al.. (2007)
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Cancer Immun, 7: 20. [PMID:18088084]

3. Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P et al.. (2014)
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
Clin Cancer Res, 20 (23): 5927-36. [PMID:25231400]

4. Ma J, Tang WK, Esser L, Pastan I, Xia D. (2012)
Characterization of crystals of an antibody-recognition fragment of the cancer differentiation antigen mesothelin in complex with the therapeutic antibody MORAb-009.
Acta Crystallogr Sect F Struct Biol Cryst Commun, 68 (Pt 8): 950-3. [PMID:22869130]

5. Tang Z, Qian M, Ho M. (2013)
The role of mesothelin in tumor progression and targeted therapy.
Anticancer Agents Med Chem, 13 (2): 276-80. [PMID:22721387]